Doximity/$DOCS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Doximity
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
- Ticker
- $DOCS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 880
- Headquarters
- San Francisco, United States
- Website
- www.doximity.com
Doximity Metrics
BasicAdvanced
$5.6B
43.18
$0.72
1.29
-
Price and volume
Market cap
$5.6B
Beta
1.29
52-week high
$51.85
52-week low
$17.15
Average daily volume
2.7M
Financial strength
Current ratio
6.373
Quick ratio
6.132
Long term debt to equity
0.007
Total debt to equity
0.01
Profitability
EBITDA (TTM)
184.248
Gross margin (TTM)
86.83%
Net profit margin (TTM)
21.12%
Operating margin (TTM)
27.12%
Effective tax rate (TTM)
31.38%
Revenue per employee (TTM)
$750,000
Management effectiveness
Return on assets (TTM)
9.55%
Return on equity (TTM)
13.81%
Valuation
Price to earnings (TTM)
43.184
Price to revenue (TTM)
8.624
Price to book
5.98
Price to tangible book (TTM)
6.83
Price to free cash flow (TTM)
19.229
Free cash flow yield (TTM)
5.20%
Free cash flow per share (TTM)
1.618
Growth
Revenue change (TTM)
6.48%
Earnings per share change (TTM)
-42.31%
3-year revenue growth (CAGR)
13.85%
3-year earnings per share growth (CAGR)
7.47%
What the Analysts think about Doximity
Analyst ratings (Buy, Hold, Sell) for Doximity stock.
Analyst projections of the future price of Doximity stock.
Bulls say / Bears say
Doximity’s workflow tools are gaining traction: active workflow prescribers rose more than 30% year on year, while AI search queries grew over 25% quarter on quarter. Greater use gives the company more opportunities to monetise its physician network. (SEC)
Early commercial AI Search economics look promising: management said revenue per search was more than ten times the cost to serve it, and the first customer programmes were being onboarded. Longer, larger contracts could make AI Search a meaningful new revenue stream if this early interest converts. (CNBC, The Motley Fool)
Hospital uptake gives Doximity a potential growth channel beyond pharmaceutical advertising: it had signed 165 health-system AI clients and was expanding its clinical tools across hospital workflows. Enterprise deployments could make Ask and Scribe more embedded in clinicians’ daily work. (Fierce Healthcare)
Near-term growth remains subdued: management’s fiscal 2027 revenue guidance implies about 5% growth, and its second-quarter outlook implies roughly 1%. Tight pharma budgets and shorter customer commitments limit visibility into a faster recovery. (The Motley Fool)
The shares may leave little room for execution errors: Wells Fargo argued that Doximity’s valuation reflected compounder-level expectations despite market-like growth, while AI monetisation remained unproven. If the new products do not accelerate growth, that gap could weigh on the stock. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
Doximity Financial Performance
Revenues and expenses
Doximity Earnings Performance
Company profitability
Upcoming events
No upcoming events
Doximity News
AllArticlesVideos

DOXIMITY DEADLINE: ROSEN, A TOP-RANKED LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - DOCS
Newsfile Corp5 days ago

Doximity to Provide New Clinical AI Tools Across NewYork-Presbyterian, Columbia University and Weill Cornell Medicine
Business Wire6 days ago

DOXIMITY DEADLINE: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - DOCS
Newsfile Corp6 days ago
Funds containing Doximity
Fund name | Fund size | $DOCS weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $5.9B | 0.12% |
SPDR S&P 400 US Mid Cap£SPX4 | $5.9B | 0.12% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $2.7B | 0.05% |
iShares MSCI World Small Cap€IUSN | $9B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.